驻国家卫生健康委纪检监察组聚焦整治重点 加力推进医药领域纠风治乱

Core Viewpoint - The central government is intensifying efforts to purify the political and industry ecology in the pharmaceutical sector, emphasizing the necessity of maintaining the public's interests through strict supervision and anti-corruption measures [2]. Group 1: Anti-Corruption Measures - The Central Commission for Discipline Inspection and the National Supervisory Commission are focusing on addressing issues such as medical staff accepting "red envelopes," misusing academic exchanges for personal gain, and exploiting multi-point practice for personal profit [2][3]. - A set of nine implementation rules for the integrity of medical institution staff is being developed to enforce prohibitive regulations and curb unethical practices in the industry [2]. Group 2: Specific Initiatives - The supervisory group is conducting targeted research and interviews with doctors from various hospitals to identify key issues and propose actionable recommendations for improvement [3]. - A national action plan for the special rectification of medical ethics and conduct is being drafted, alongside the introduction of the "Professional Ethics Code for Medical Staff (2025 Edition)" to guide ethical behavior among healthcare professionals [3]. Group 3: Regulatory Oversight - The National Health Commission is initiating a year-long special rectification of medical quality and safety in hospitals, starting from June, to enhance the mechanisms for quality assurance and emergency response [3]. - A total of 47,000 medical institutions have been randomly inspected to address issues such as repeated medical examinations and illegal charges, with a focus on regulatory compliance and corrective actions [4]. Group 4: Future Focus - The supervisory group plans to maintain a strict focus on key personnel and critical areas such as drug procurement, high-value consumables, and medical equipment purchases, adopting a zero-tolerance approach towards misconduct and corruption [4].